Citadel Advisors’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Citadel Advisors’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,200	Closed	-$1.98K	–	15949
2022 Q4	$1.98K	Sell	2,200 -9,000	-80%	-$26.1K	﹤0.01%	14393
2022 Q3	$67K	Buy	+11,200	New	+$63.5K	﹤0.01%	11420
2021 Q4	–	Sell	-13,300	Closed	-$62K	–	15156
2021 Q3	$62K	Buy	+13,300	New	+$70.5K	﹤0.01%	13247

Citadel Advisors's STSA Position: Q2 2023 in Review

Citadel Advisors sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 5,397 shares — an estimated $3.77K sold.

Citadel Advisors first reported a position in STSA in Q3 2019 and held it in 14 quarters. The position peaked at $29.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

Citadel Advisors reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 5,397 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $3.77K.
Citadel Advisors first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 14 quarters.
Citadel Advisors's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $29.6M in Q2 2020.
0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.